

How Do We Measure Leverage? Let Us Count the Ways

Shobhit Gupta
+1 212 412 2056
shobhit.gupta@barclays.com

Ryan Preclaw, CFA
+1 212 412 2249
ryan.preclaw@barclays.com


Bruno Velloso
+1 212 412 2345
bruno.velloso@barclays.com

In the recently published report, *U.S. Credit Focus: A Great Deleveraging: Why It Is Happening and What It Means for Equities*, April 24, 2015, the equity and credit strategy research teams determined that, contrary to conventional wisdom, leverage should decline during periods of lower interest rates. The most common objection we have heard to that conclusion was that the measure of leverage highlighted as evidence – debt to book equity – was not the best metric, and that other methods in fact show leverage to be rising. We think that measuring leverage for an index or portfolio is more complex than is normally appreciated (for example, see the *U.S. Credit Alpha: Leveraging Complexity*, April 2014), so we thought it would be timely to examine what different measures of leverage tell us (and the trade-offs between them).

No matter how we measure leverage, though, our underlying conclusion remains the same: non-financial leverage in the U.S. Corporate Index is significantly lower than it was in the early 2000s and only modestly above a post-crisis trough. And none of our measures shows leverage rising anything close to proportionately to the fall in interest rates.


- It is undeniable that leverage has increased since the 2010 trough. Of the 16 measures of leverage we discuss in this article, 13 have risen since 2010.
- But it seems just as clear that the leverage increase has been a matter of picking the measurement period. All 16 measures are below their 2002 levels, three are below their 2007 levels, and 10 are below 2009 levels.
- Finally, because companies tend to build their optimal capital structures based on future operating performance, much of the difference in high and low leverage occurs when EBITDA surprises to the upside or downside. In 2010, for example – a post-crisis trough in leverage – EBITDA surprised to the upside; meanwhile, in 2014, realized EBITDA missed expectations significantly. Adjusting for this difference, leverage between 2010 and 2014 was essentially flat.

FIGURE 1
Debt/EBITDA Simple Average and Median



Note: Non-financial issuers only in the U.S. Corporate Index.
Source: FactSet, Barclays Research

FIGURE 2
Debt/EBITDA Index-Weighted Average and Aggregated



Note: Non-financial issuers only in the U.S. Corporate Index.
Source: FactSet, Barclays Research

Sensible Aggregate Leverage Starts with Minor Adjustments

The starting point for aggregate measures of leverage is understanding the basic adjustments that need to be made to raw leverage data to develop a sensible and informative series. In our view, debt to EBITDA is the preferred measure of credit investors. But the nature of those data creates difficulties in aggregation:

- A simple average of all companies has the benefit of simplicity. But there is significant downside because debt/EBITDA is unbounded in any particular period. If an issuer realizes a one-time loss that results in very low EBITDA, leverage can be high enough to move the entire average – for example, the large spike in 2010 was driven primarily by one company, among nearly 400 data points, that showed over 500x leverage because of very low EBITDA in that year. Even worse is when EBITDA goes negative – leverage will also be negative. As a result, the series is much more volatile than the reality of the underlying corporate behavior and performance (Figure 1).
 - One option is to smooth the series by doing some pre-processing on the data. We make two simple adjustments throughout the rest of this report, excluding firms that have leverage higher than 30x and that have negative EBITDA. These simple adjustments exclude no more than 10 firms in any year (fewer than 2% of the universe), but remove a substantial amount of volatility (Figure 1)
- Using a median rather than an average smoothes the data significantly (Figure 1), but can mask the very changes that most investors would consider most important. We can show this with a stylized example. Let's say an index has 10 issuers, of which six are A-rated firms with stable financial policies in stable markets, but four are more flexible or facing operating challenges. In one year, the stable firms have 2x leverage and the challenged firms have 3x; the median is 2x. Let's say that the following year, the challenges come home to roost – some of the less stable firms see poor operating results, and others actively choose to pursue higher leverage – with the result that the four weaker firms see leverage rise to 6x on average. Because the stable firms have not moved, the median remains 2x, even though investors would clearly see higher risk in owning the whole group.
- An aggregate measure, adding up all the debt and all the EBITDA and then taking the ratio, is also smoother than the simple average and captures the tails more accurately than the median (Figure 2). But it puts more weight on very large firms, which pulls the average toward their degree of leverage. For example, when Apple (AAPL) entered the U.S. Corporate Index in 2013, it had about \$60bn of EBITDA, but only about \$16bn of debt in the index. So if, for example, the aggregate index prior to AAPL had \$4trn of debt and \$2trn of EBITDA for an aggregate leverage of 2x, after AAPL joined, leverage would have fallen to 1.95x. As a result, a relatively small number of firms can skew the overall results away from what investors are actually exposed to in their holdings. This effect is compounded for measures of net leverage because some firms hold a disproportionate amount of cash.
- Finally, a full distribution measure, such as index-weighted leverage, reflects the actual exposures that investors benchmarked to the U.S. Corporate Index face. While, like the aggregate measure above, these measures are difficult to calculate and can be skewed in the direction of firms with a disproportionate share of the index bonds outstanding, we believe they are the most closely matched to what credit investors actually face in their portfolios, are smoother than simple averages, and, unlike medians, capture a proportionate effect from shifts in the tails (Figure 2).

Many Different Measures, Mostly Pointing in the Same Direction

Even once we make the necessary adjustments needed to make sense of a given series, different measure of leverage can suggest different trends. We look at what five measures – total debt/EBITDA, net debt/EBITDA, total debt/EV, total debt/total assets, and total


debt/1y forward consensus EBITDA – are telling us about trends and discuss the trade-offs of each series.

Total Debt/EBITDA and Net Debt/EBITDA

Gross and net leverage as measured by debt/LTM EBITDA show that non-financial leverage has been stable within a 0.3x range since the mid-2000s (Figures 3 and 4). While there has been an uptick more recently (median gross leverage has increased to 2.06x, from 2.02x in 2012 and 1.83x in 2006), both net and gross leverage are well below early-2000 levels, when rates were much higher than they are now. Net leverage has, if anything, been even more stable. The clearest uptick has come in the index-weighted series, which is still close to 2005-08 levels (and well below the early 2000s).


- **Total debt/EBITDA** benefits from measuring leverage relative to the ability to service that obligation. It also reflects a conservative measure from the creditor's perspective – it implicitly assumes that management will have disposed of any cash balances before they would have been useful to creditors. The measure reflects realized and recent operating results.
 - Considerations for using total debt/EBITDA include an overemphasis on results that could be transient (whether good or bad) – it will tend to move cyclically, even when corporate behavior and performance are relatively unchanged. Because it is backward-looking, it does not reflect the forward-looking perspective of both management and investors. It provides non-meaningful results for companies with negative EBITDA. Moreover, It fails to account for underlying assets (including cash), which could be important in downside cases.
- **Net debt/EBITDA** reflects the likelihood that cash would provide companies with a cushion that can benefit creditors – while less conservative, it is more likely to reflect how corporate behavior would evolve.
 - In aggregations, cash balances can skew the results of the entire index. In the example above of Apple entering the index, if the pre-existing constituents had an aggregate \$1trn of cash for net leverage of 1.5x, AAPL's \$150bn of cash would have moved the overall index's net leverage to 1.39x. That 0.11x move in the index would have been larger than half of the single-year moves since 2005.

FIGURE 3
Total Debt/EBITDA since 2000




Note: Non-financial issuers only in the U.S. Corporate Index.
Source: FactSet, Barclays Research

FIGURE 4
Net Debt/EBITDA since 2000



Note: Non-financial issuers only in the U.S. Corporate Index.
Source: FactSet, Barclays Research

FIGURE 5

Total Debt to Enterprise Value since 2000

Note: Non-financial issuers only in the U.S. Corporate Index. Source: FactSet, Barclays Research

Total Debt/Enterprise Value


Unlike debt/EBITDA, debt/EV (or debt/market capitalization) shows a significant decline in leverage post-crisis. While this is, in part, affected by higher equity valuations across the market, the decline has been meaningful. Median debt/EV has declined from 30% in 2008 to 20% (Figure 5). Moreover, leverage is significantly lower than early-2000 levels, and the aggregate series remains roughly in line with 2005-07 trough levels.

- **Debt/EV** benefits from being a forward-looking measure, given that the equity component captures the future value of the company. As such, it is likely to reflect policy decisions by management and changes in investor sentiment more quickly. It is also bounded between zero and one (except in unusual cases), which means it does not suffer from the scaling issues that require us to exclude some issuers from the simple averages.
 - On the downside, the sensitivity to equity valuations makes companies with overvalued stocks look stronger than they might really be. Conversely, companies with undervalued stocks will look misleadingly weak. It does not directly capture the capacity of the company to meet its obligations with cash flow – an issuer could be highly valued, but with relatively little flexibility to service debt in the case of some sort of shock, and this measure would not be able to fully capture that.

Total Debt/Total Assets

This metric shows a moderate increase in leverage since 2010. However, put in a historical context, a roughly 1-2% increase in debt/assets over four years is not a very large jump; there were several single years in which debt/assets moved by more than 2% (Figure 6). Furthermore, debt/assets is still below early-2000 and 2008 levels, showing that while leverage may have ticked up in the past few years, it is still structurally lower than in previous periods, which corroborates previous leverage measures.

FIGURE 6
Total Debt/Total Assets since 2000



Note: Non-financial issuers only in the U.S. Corporate Index. Source: FactSet, Barclays Research


- **Total Debt/Assets** is a more stable measure of credit strength that is less subject to the fluctuations in operating performance or market value. Barring changes in asset markets, it directly captures the protection that creditors have in the worst case scenario where an issuer was liquidated. When aggregated, it does suggest the relative safety that a credit portfolio might have against an extreme macro swing.
 - Because it is based on book value the metric does not account fully for changing market perception/valuations of the company – book values can differ from the prices assets could be sold for in the market. Because it is backwards looking, it doesn't necessarily reflect changes in management policies.

Total Debt/1y Forward Consensus EBITDA

In our view, the metric that best captures management policies is the ratio of total debt to one-year-forward consensus EBITDA. This is because companies tend to build their optimal capital structures based on expectations of future operating performance. In *U.S. Credit Focus: Weaker Fundamentals, Same Price*, October 25, 2013, we found that one of the best predictors of corporate debt issuance in the next year was expected growth in EBITDA. Our model suggested that investment grade corporate issuers move their leverage toward an average target of around 2x debt/EBITDA; they add debt when EBITDA is expected to grow and limit issuance when EBITDA is expected to shrink. Therefore, significant changes in leverage are more likely to come from either unexpectedly strong years (when leverage is low because operating performance exceeded EBITDA expectations) or unexpectedly weak years (when the opposite occurs). In Figures 2-5, for example, 2008-09 is when leverage spiked, in the wake of weaker-than-expected earnings results.

FIGURE 7


Median Total Debt/1y Forward EBITDA



Note: Non-financial issuers only in the U.S. Corporate Index. Source: FactSet, Barclays Research

FIGURE 8

Median Net Debt/1y Forward EBITDA




Note: Non-financial issuers only in the U.S. Corporate Index. Source: FactSet, Barclays Research

Figure 7 supports our leverage-target thesis, with median gross leverage numbers stable around 1.7-1.8x, showing that companies seem to aim for a leverage of just below 2x based on consensus EBITDA expectations. Median net leverage is also stable, but it shows a bit more of a decline over time (Figure 8). Although this measure suffers from some of the drawbacks of using debt/EBITDA, it does add a forward-looking component and does not penalize companies for one-time events that may have affected free cash flow generation only in the most recent period.

To quantify this effect, we looked at actual versus forecast EBITDA numbers for 2010 and 2014. As Figure 9 shows, 2014 actual EBITDA was well below the consensus estimate at YE 2013. This is likely behind the uptick in leverage; the actual 2014 number was about 6% lower than the estimated amount. Conversely, in 2010, actual EBITDA was 2% higher than YE 2009 consensus estimates, which means that actual leverage should have overshot expectations. By adjusting 2010 and 2014 median debt/EBITDA to reflect the consensus estimates (Figure 10), we find that the difference in leverage goes away almost entirely (only 0.06x apart).

FIGURE 9


Aggregate 2014 EBITDA Was Lower Than Early Expectations



Note: Non-financial issuers only in the U.S. Corporate Index. Source: FactSet, Barclays Research


FIGURE 10

Leverage Tends to Fall in Years When Aggregate EBITDA Beats Expectations, but Rise When It Misses




Note: Non-financial issuers only in the U.S. Corporate Index. Estimates based on YE 2009 and YE 2013, respectively. Source: FactSet, Barclays Research

CDX.IG OTR Market versus Intrinsic (bp)




Source: Barclays Research

Investment Grade Fund Flows (\$bn)




Source: Lipper/Thomson Reuters, Barclays Research

CDX.IG versus VIX



Source: Markit, Barclays Research

CDS-Cash Basis (bp)



Note: Basis defined as CDX.IG spread – Corporate Libor OAS.
Source: Barclays Research

Analyst Certification

We, Shobhit Gupta, Ryan Preclaw, CFA and Bruno Velloso, hereby certify (1) that the views expressed in this research report accurately reflect our personal views about any or all of the subject securities or issuers referred to in this research report and (2) no part of our compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

Important Disclosures:

Barclays Research is a part of the Investment Bank of Barclays Bank PLC and its affiliates (collectively and each individually, "Barclays"). For current important disclosures regarding companies that are the subject of this research report, please send a written request to: Barclays Research Compliance, 745 Seventh Avenue, 14th Floor, New York, NY 10019 or refer to <http://publicresearch.barclays.com> or call 212-526-1072.

Barclays Capital Inc. and/or one of its affiliates does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that Barclays may have a conflict of interest that could affect the objectivity of this report. Barclays Capital Inc. and/or one of its affiliates regularly trades, generally deals as principal and generally provides liquidity (as market maker or otherwise) in the debt securities that are the subject of this research report (and related derivatives thereof). Barclays trading desks may have either a long and / or short position in such securities, other financial instruments and / or derivatives, which may pose a conflict with the interests of investing customers. Where permitted and subject to appropriate information barrier restrictions, Barclays fixed income research analysts regularly interact with its trading desk personnel regarding current market conditions and prices. Barclays fixed income research analysts receive compensation based on various factors including, but not limited to, the quality of their work, the overall performance of the firm (including the profitability of the Investment Banking Department), the profitability and revenues of the Markets business and the potential interest of the firm's investing clients in research with respect to the asset class covered by the analyst. To the extent that any historical pricing information was obtained from Barclays trading desks, the firm makes no representation that it is accurate or complete. All levels, prices and spreads are historical and do not represent current market levels, prices or spreads, some or all of which may have changed since the publication of this document. The Investment Bank's Research Department produces various types of research including, but not limited to, fundamental analysis, equity-linked analysis, quantitative analysis, and trade ideas. Recommendations contained in one type of research may differ from recommendations contained in other types of research, whether as a result of differing time horizons, methodologies, or otherwise. Unless otherwise indicated, trade ideas contained herein are provided as of the date of this report and are subject to change without notice due to changes in prices. In order to access Barclays Statement regarding Research Dissemination Policies and Procedures, please refer to <https://live.barcap.com/publiccp/RSR/nyfipubs/disclaimer/disclaimer-research-dissemination.html>. In order to access Barclays Research Conflict Management Policy Statement, please refer to: <https://live.barcap.com/publiccp/RSR/nyfipubs/disclaimer/disclaimer-conflict-management.html>.

Disclaimer

This publication has been prepared by the Investment Bank of Barclays Bank PLC and/or one or more of its affiliates (collectively and each individually, "Barclays"). It has been issued by one or more Barclays legal entities that are a part of the Investment Bank as provided below. It is provided to our clients for information purposes only, and Barclays makes no express or implied warranties, and expressly disclaims all warranties of merchantability or fitness for a particular purpose or use with respect to any data included in this publication. Barclays will not treat unauthorized recipients of this report as its clients. Prices shown are indicative and Barclays is not offering to buy or sell or soliciting offers to buy or sell any financial instrument.

Without limiting any of the foregoing and to the extent permitted by law, in no event shall Barclays, nor any affiliate, nor any of their respective officers, directors, partners, or employees have any liability for (a) any special, punitive, indirect, or consequential damages; or (b) any lost profits, lost revenue, loss of anticipated savings or loss of opportunity or other financial loss, even if notified of the possibility of such damages, arising from any use of this publication or its contents.

Other than disclosures relating to Barclays, the information contained in this publication has been obtained from sources that Barclays Research believes to be reliable, but Barclays does not represent or warrant that it is accurate or complete. Barclays is not responsible for, and makes no warranties whatsoever as to, the content of any third-party web site accessed via a hyperlink in this publication and such information is not incorporated by reference.

The views in this publication are those of the author(s) and are subject to change, and Barclays has no obligation to update its opinions or the information in this publication. The analyst recommendations in this publication reflect solely and exclusively those of the author(s), and such opinions were prepared independently of any other interests, including those of Barclays and/or its affiliates. This publication does not constitute personal investment advice or take into account the individual financial circumstances or objectives of the clients who receive it. The securities discussed herein may not be suitable for all investors. Barclays recommends that investors independently evaluate each issuer, security or instrument discussed herein and consult any independent advisors they believe necessary. The value of and income from any investment may fluctuate from day to day as a result of changes in relevant economic markets (including changes in market liquidity). The information herein is not intended to predict actual results, which may differ substantially from those reflected. Past performance is not necessarily indicative of future results.

This material has been issued and approved for distribution in the UK and European Economic Area by Barclays Bank PLC. It is being made available primarily to persons who are investment professionals as that term is defined in Article 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005. It is directed at, and therefore should only be relied upon by, persons who have professional experience in matters relating to investments. The investments to which it relates are available only to such persons and will be entered into only with such persons. Barclays Bank PLC is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority and is a member of the London Stock Exchange.

The Investment Bank of Barclays Bank PLC undertakes U.S. securities business in the name of its wholly owned subsidiary Barclays Capital Inc., a FINRA and SIPC member. Barclays Capital Inc., a U.S. registered broker/dealer, is distributing this material in the United States and, in connection therewith accepts responsibility for its contents. Any U.S. person wishing to effect a transaction in any security discussed herein should do so only by contacting a representative of Barclays Capital Inc. in the U.S. at 745 Seventh Avenue, New York, New York 10019.

Non-U.S. persons should contact and execute transactions through a Barclays Bank PLC branch or affiliate in their home jurisdiction unless local regulations permit otherwise.

Barclays Bank PLC, Paris Branch (registered in France under Paris RCS number 381 066 281) is regulated by the Autorité des marchés financiers and the Autorité de contrôle prudentiel. Registered office 34/36 Avenue de Friedland 75008 Paris.

This material is distributed in Canada by Barclays Capital Canada Inc., a registered investment dealer, a Dealer Member of IIROC (www.iiroc.ca), and a Member of the Canadian Investor Protection Fund (CIPF).

Subject to the conditions of this publication as set out above, the Corporate & Investment Banking Division of Absa Bank Limited, an authorised financial

services provider (Registration No.: 1986/004794/06. Registered Credit Provider Reg No NCRCP7), is distributing this material in South Africa. Absa Bank Limited is regulated by the South African Reserve Bank. This publication is not, nor is it intended to be, advice as defined and/or contemplated in the (South African) Financial Advisory and Intermediary Services Act, 37 of 2002, or any other financial, investment, trading, tax, legal, accounting, retirement, actuarial or other professional advice or service whatsoever. Any South African person or entity wishing to effect a transaction in any security discussed herein should do so only by contacting a representative of the Corporate & Investment Banking Division of Absa Bank Limited in South Africa, 15 Alice Lane, Sandton, Johannesburg, Gauteng 2196. Absa Bank Limited is a member of the Barclays group.

In Japan, foreign exchange research reports are prepared and distributed by Barclays Bank PLC Tokyo Branch. Other research reports are distributed to institutional investors in Japan by Barclays Securities Japan Limited. Barclays Securities Japan Limited is a joint-stock company incorporated in Japan with registered office of 6-10-1 Roppongi, Minato-ku, Tokyo 106-6131, Japan. It is a subsidiary of Barclays Bank PLC and a registered financial instruments firm regulated by the Financial Services Agency of Japan. Registered Number: Kanto Zaimukyokuchō (kinsho) No. 143.

Barclays Bank PLC, Hong Kong Branch is distributing this material in Hong Kong as an authorised institution regulated by the Hong Kong Monetary Authority. Registered Office: 41/F, Cheung Kong Center, 2 Queen's Road Central, Hong Kong.

Information on securities/instruments that trade in Taiwan or written by a Taiwan-based research analyst is distributed by Barclays Capital Securities Taiwan Limited to its clients. The material on securities/instruments not traded in Taiwan is not to be construed as 'recommendation' in Taiwan. Barclays Capital Securities Taiwan Limited does not accept orders from clients to trade in such securities. This material may not be distributed to the public media or used by the public media without prior written consent of Barclays.

This material is distributed in South Korea by Barclays Capital Securities Limited, Seoul Branch.

All Indian securities related research and other equity research are distributed in India by Barclays Securities (India) Private Limited (BSIPL). BSIPL is a company incorporated under the Companies Act, 1956 having CIN U67120MH2006PTC161063. BSIPL is registered and regulated by the Securities and Exchange Board of India (SEBI) as a Portfolio Manager INP000002585; Stock Broker/Trading and Clearing Member: National Stock Exchange of India Limited (NSE) Capital Market INB231292732, NSE Futures & Options INF231292732, NSE Currency derivatives INE231450334, Bombay Stock Exchange Limited (BSE) Capital Market INB011292738, BSE Futures & Options INF011292738; Merchant Banker: INM000011195; Depository Participant (DP) with the National Securities & Depositories Limited (NSDL): DP ID: IN-DP-NSDL-299-2008; Investment Adviser: INA000000391. The registered office of BSIPL is at 208, Ceejay House, Shivsagar Estate, Dr. A. Besant Road, Worli, Mumbai – 400 018, India. Telephone No: +91 22 67196000. Fax number: +91 22 67196100. Any other reports are distributed in India by Barclays Bank PLC, India Branch.

Barclays Bank PLC Frankfurt Branch distributes this material in Germany under the supervision of Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin).

This material is distributed in Malaysia by Barclays Capital Markets Malaysia Sdn Bhd.

This material is distributed in Brazil by Banco Barclays S.A.

This material is distributed in Mexico by Barclays Bank Mexico, S.A.

Barclays Bank PLC in the Dubai International Financial Centre (Registered No. 0060) is regulated by the Dubai Financial Services Authority (DFSA). Principal place of business in the Dubai International Financial Centre: The Gate Village, Building 4, Level 4, PO Box 506504, Dubai, United Arab Emirates. Barclays Bank PLC-DIFC Branch, may only undertake the financial services activities that fall within the scope of its existing DFSA licence. Related financial products or services are only available to Professional Clients, as defined by the Dubai Financial Services Authority.

Barclays Bank PLC in the UAE is regulated by the Central Bank of the UAE and is licensed to conduct business activities as a branch of a commercial bank incorporated outside the UAE in Dubai (Licence No.: 13/1844/2008, Registered Office: Building No. 6, Burj Dubai Business Hub, Sheikh Zayed Road, Dubai City) and Abu Dhabi (Licence No.: 13/952/2008, Registered Office: Al Jazira Towers, Hamdan Street, PO Box 2734, Abu Dhabi).

Barclays Bank PLC in the Qatar Financial Centre (Registered No. 00018) is authorised by the Qatar Financial Centre Regulatory Authority (QFCRA). Barclays Bank PLC-QFC Branch may only undertake the regulated activities that fall within the scope of its existing QFCRA licence. Principal place of business in Qatar: Qatar Financial Centre, Office 1002, 10th Floor, QFC Tower, Diplomatic Area, West Bay, PO Box 15891, Doha, Qatar. Related financial products or services are only available to Business Customers as defined by the Qatar Financial Centre Regulatory Authority.

This material is distributed in the UAE (including the Dubai International Financial Centre) and Qatar by Barclays Bank PLC.

This material is distributed in Russia by OOO Barclays Capital, affiliated company of Barclays Bank PLC, registered and regulated in Russia by the FSFM. Broker License #177-11850-100000; Dealer License #177-11855-010000. Registered address in Russia: 125047 Moscow, 1st Tverskaya-Yamskaya str. 21.

This material is distributed in Singapore by the Singapore branch of Barclays Bank PLC, a bank licensed in Singapore by the Monetary Authority of Singapore. For matters in connection with this report, recipients in Singapore may contact the Singapore branch of Barclays Bank PLC, whose registered address is One Raffles Quay Level 28, South Tower, Singapore 048583.

Barclays Bank PLC, Australia Branch (ARBN 062 449 585, AFSL 246617) is distributing this material in Australia. It is directed at 'wholesale clients' as defined by Australian Corporations Act 2001.

IRS Circular 230 Prepared Materials Disclaimer: Barclays does not provide tax advice and nothing contained herein should be construed to be tax advice. Please be advised that any discussion of U.S. tax matters contained herein (including any attachments) (i) is not intended or written to be used, and cannot be used, by you for the purpose of avoiding U.S. tax-related penalties; and (ii) was written to support the promotion or marketing of the transactions or other matters addressed herein. Accordingly, you should seek advice based on your particular circumstances from an independent tax advisor.

© Copyright Barclays Bank PLC (2015). All rights reserved. No part of this publication may be reproduced or redistributed in any manner without the prior written permission of Barclays. Barclays Bank PLC is registered in England No. 1026167. Registered office 1 Churchill Place, London, E14 5HP. Additional information regarding this publication will be furnished upon request.

